vs

Side-by-side financial comparison of Alkermes plc. (ALKS) and Planet Fitness, Inc. (PLNT). Click either name above to swap in a different company.

Alkermes plc. is the larger business by last-quarter revenue ($384.5M vs $376.3M, roughly 1.0× Planet Fitness, Inc.). Planet Fitness, Inc. runs the higher net margin — 16.0% vs 12.8%, a 3.2% gap on every dollar of revenue. On growth, Planet Fitness, Inc. posted the faster year-over-year revenue change (10.5% vs -10.6%). Alkermes plc. produced more free cash flow last quarter ($170.0M vs $59.0M). Over the past eight quarters, Planet Fitness, Inc.'s revenue compounded faster (23.2% CAGR vs 4.8%).

Alkermes plc is a fully-integrated biopharmaceutical company that focuses on developing medicines for psychiatric and neurological disorders. The company was founded in 1987 by Michael Wall. In September 2011 Alkermes, Inc. merged with Elan Drug Technologies (EDT), the former drug formulation and manufacturing division of Élan Corporation, plc. The company is headquartered in Dublin, and has an R&D center in Waltham, Massachusetts, and a manufacturing facility in Wilmington, Ohio.

Planet Fitness, Inc. is an American franchisor and operator of fitness centers based in Hampton, New Hampshire. The company has around 2,715 clubs, making it one of the largest fitness club franchises by number of members and locations. The franchise has locations in the United States, Canada, Panama, Mexico, Spain and Australia. It markets itself as a "Judgement Free Zone" open to all levels of gym users.

ALKS vs PLNT — Head-to-Head

Bigger by revenue
ALKS
ALKS
1.0× larger
ALKS
$384.5M
$376.3M
PLNT
Growing faster (revenue YoY)
PLNT
PLNT
+21.1% gap
PLNT
10.5%
-10.6%
ALKS
Higher net margin
PLNT
PLNT
3.2% more per $
PLNT
16.0%
12.8%
ALKS
More free cash flow
ALKS
ALKS
$111.1M more FCF
ALKS
$170.0M
$59.0M
PLNT
Faster 2-yr revenue CAGR
PLNT
PLNT
Annualised
PLNT
23.2%
4.8%
ALKS

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
ALKS
ALKS
PLNT
PLNT
Revenue
$384.5M
$376.3M
Net Profit
$49.3M
$60.4M
Gross Margin
88.0%
76.0%
Operating Margin
15.1%
28.2%
Net Margin
12.8%
16.0%
Revenue YoY
-10.6%
10.5%
Net Profit YoY
-66.3%
28.3%
EPS (diluted)
$0.29

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ALKS
ALKS
PLNT
PLNT
Q4 25
$384.5M
$376.3M
Q3 25
$394.2M
$330.3M
Q2 25
$390.7M
$340.9M
Q1 25
$306.5M
$276.7M
Q4 24
$430.0M
$340.4M
Q3 24
$378.1M
$292.2M
Q2 24
$399.1M
$300.9M
Q1 24
$350.4M
$248.0M
Net Profit
ALKS
ALKS
PLNT
PLNT
Q4 25
$49.3M
$60.4M
Q3 25
$82.8M
$58.8M
Q2 25
$87.1M
$58.0M
Q1 25
$22.5M
$41.9M
Q4 24
$146.5M
$47.1M
Q3 24
$92.4M
$42.0M
Q2 24
$91.4M
$48.6M
Q1 24
$36.8M
$34.3M
Gross Margin
ALKS
ALKS
PLNT
PLNT
Q4 25
88.0%
76.0%
Q3 25
86.9%
82.4%
Q2 25
87.3%
82.6%
Q1 25
83.9%
91.9%
Q4 24
85.6%
76.4%
Q3 24
83.3%
84.4%
Q2 24
84.6%
82.7%
Q1 24
83.3%
92.3%
Operating Margin
ALKS
ALKS
PLNT
PLNT
Q4 25
15.1%
28.2%
Q3 25
22.6%
32.4%
Q2 25
23.8%
30.0%
Q1 25
4.5%
28.6%
Q4 24
37.8%
26.4%
Q3 24
27.7%
27.8%
Q2 24
27.5%
29.0%
Q1 24
12.4%
26.5%
Net Margin
ALKS
ALKS
PLNT
PLNT
Q4 25
12.8%
16.0%
Q3 25
21.0%
17.8%
Q2 25
22.3%
17.0%
Q1 25
7.3%
15.1%
Q4 24
34.1%
13.8%
Q3 24
24.4%
14.4%
Q2 24
22.9%
16.2%
Q1 24
10.5%
13.8%
EPS (diluted)
ALKS
ALKS
PLNT
PLNT
Q4 25
$0.29
Q3 25
$0.49
Q2 25
$0.52
Q1 25
$0.13
Q4 24
$0.88
Q3 24
$0.55
Q2 24
$0.53
Q1 24
$0.21

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ALKS
ALKS
PLNT
PLNT
Cash + ST InvestmentsLiquidity on hand
$388.6M
$452.4M
Total DebtLower is stronger
$2.5B
Stockholders' EquityBook value
$1.8B
$-482.8M
Total Assets
$2.5B
$3.1B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ALKS
ALKS
PLNT
PLNT
Q4 25
$388.6M
$452.4M
Q3 25
$616.4M
$443.4M
Q2 25
$521.2M
$442.7M
Q1 25
$399.8M
$453.6M
Q4 24
$291.1M
$407.3M
Q3 24
$396.3M
$407.4M
Q2 24
$535.1M
$350.2M
Q1 24
$420.8M
$395.1M
Total Debt
ALKS
ALKS
PLNT
PLNT
Q4 25
$2.5B
Q3 25
$2.2B
Q2 25
$2.2B
Q1 25
$2.2B
Q4 24
$2.2B
Q3 24
$2.2B
Q2 24
$2.2B
Q1 24
$2.0B
Stockholders' Equity
ALKS
ALKS
PLNT
PLNT
Q4 25
$1.8B
$-482.8M
Q3 25
$1.7B
$-194.8M
Q2 25
$1.6B
$-158.7M
Q1 25
$1.5B
$-219.9M
Q4 24
$1.5B
$-215.4M
Q3 24
$1.3B
$-266.1M
Q2 24
$1.3B
$-317.7M
Q1 24
$1.3B
$-96.4M
Total Assets
ALKS
ALKS
PLNT
PLNT
Q4 25
$2.5B
$3.1B
Q3 25
$2.3B
$3.1B
Q2 25
$2.3B
$3.1B
Q1 25
$2.1B
$3.1B
Q4 24
$2.1B
$3.1B
Q3 24
$2.2B
$3.0B
Q2 24
$2.2B
$3.0B
Q1 24
$2.1B
$3.0B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ALKS
ALKS
PLNT
PLNT
Operating Cash FlowLast quarter
$170.1M
$109.1M
Free Cash FlowOCF − Capex
$170.0M
$59.0M
FCF MarginFCF / Revenue
44.2%
15.7%
Capex IntensityCapex / Revenue
0.0%
13.3%
Cash ConversionOCF / Net Profit
3.45×
1.81×
TTM Free Cash FlowTrailing 4 quarters
$480.3M
$254.8M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ALKS
ALKS
PLNT
PLNT
Q4 25
$170.1M
$109.1M
Q3 25
$101.7M
$131.5M
Q2 25
$150.2M
$44.0M
Q1 25
$98.8M
$133.9M
Q4 24
$190.4M
$49.1M
Q3 24
$81.6M
$126.8M
Q2 24
$146.0M
$78.2M
Q1 24
$21.1M
$89.7M
Free Cash Flow
ALKS
ALKS
PLNT
PLNT
Q4 25
$170.0M
$59.0M
Q3 25
$84.4M
$76.7M
Q2 25
$137.2M
$8.2M
Q1 25
$88.7M
$110.9M
Q4 24
$180.6M
$7.0M
Q3 24
$73.3M
$78.2M
Q2 24
$138.9M
$40.2M
Q1 24
$12.8M
$63.4M
FCF Margin
ALKS
ALKS
PLNT
PLNT
Q4 25
44.2%
15.7%
Q3 25
21.4%
23.2%
Q2 25
35.1%
2.4%
Q1 25
28.9%
40.1%
Q4 24
42.0%
2.1%
Q3 24
19.4%
26.7%
Q2 24
34.8%
13.4%
Q1 24
3.6%
25.6%
Capex Intensity
ALKS
ALKS
PLNT
PLNT
Q4 25
0.0%
13.3%
Q3 25
4.4%
16.6%
Q2 25
3.3%
10.5%
Q1 25
3.3%
8.3%
Q4 24
2.3%
12.4%
Q3 24
2.2%
16.6%
Q2 24
1.8%
12.6%
Q1 24
2.4%
10.6%
Cash Conversion
ALKS
ALKS
PLNT
PLNT
Q4 25
3.45×
1.81×
Q3 25
1.23×
2.23×
Q2 25
1.72×
0.76×
Q1 25
4.40×
3.20×
Q4 24
1.30×
1.04×
Q3 24
0.88×
3.02×
Q2 24
1.60×
1.61×
Q1 24
0.57×
2.62×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ALKS
ALKS

Vivitrol$124.1M32%
Aristada And Aristada Initio$97.2M25%
LYBALVI$94.1M24%
Royalty$65.7M17%
Manufacturing Revenue$3.3M1%

PLNT
PLNT

Corporate Owned Club Segment$135.6M36%
Equipment Revenue$121.2M32%
Franchise$98.6M26%
Advertising$20.8M6%
Related Party$4.3M1%

Related Comparisons